Latest News & Features
Refine Search
Americas
Guido Rasi and Luis Salaices were selected in the LSIPR 50 2016 publication for their influence on the life sciences industry. Rasi and Luis Salaices were featured in the government and policy section, as LSIPR reports. 5 October 2016
Americas
Barack Obama and Stephen Ostroff were selected in the LSIPR 50 2016 publication for their influence on the life sciences industry. Obama and Stephen Ostroff featured in the government and policy section, as LSIPR reports. 5 October 2016
Africa
Jorge Kalil and Narendra Modi were selected in the LSIPR 50 2016 publication for their influence on the life sciences industry. Kalil and Modi were featured in the government and policy section, as LSIPR reports. 5 October 2016
Americas
Francis Collins and James Greenwood were selected in the LSIPR 50 2016 publication for their influence on the life sciences industry. Collins and Greenwood featured in the government and policy section, as LSIPR reports. 5 October 2016
Americas
Jarbas Barbosa da Silva Jr and Margaret Chan were selected in the LSIPR 50 2016 publication for their influence on the life sciences industry. Love featured in the government and policy section, as LSIPR reports. 5 October 2016
Biotechnology
James Love was selected in the LSIPR 50 2016 publication for his influence on the life sciences industry. Love featured in the government and policy section, as LSIPR reports. 5 October 2016
Asia
Xi Jinping and George Freeman were selected in the LSIPR 50 2016 publication for their influence on the life sciences industry. Jinping and Freeman were featured in the government and policy section, as LSIPR reports. 5 October 2016
Europe
A decision by Germany’s Federal Court of Justice has developed the concept of the ‘doctrine of equivalents’, possibly benefiting pharma patent owners, say Bernd Allekotte and Markus Grammel of Grünecker. 20 September 2016
Big Pharma
Ahead of the Life Sciences IP Summit 2016 from October 20 to 21 at the Hilton London Paddington Hotel, Sarah Porch of C5 previews the main talking points, including Brexit and the UPC. 16 September 2016
Big Pharma
The pharmaceutical industry needs to adjust its expectations of the scope of IP protection available in the digital age, say Stephen Bennett, Elisabethann Wright and Mark Marfe of Hogan Lovells, and James Cross of RGC Jenkins. 13 September 2016